First Amendment to ONCOSIGNATURE COMPANION DIAGNOSTIC Agreement

Exhibit 10.14

First Amendment to

ONCOSIGNATURE COMPANION DIAGNOSTIC Agreement

This First Amendment to Oncosignature Companion Diagnostic Agreement (the “First Amendment”) is made and entered into as of December 21, 2022 (the “First Amendment Effective Date”) by and between:

Acrivon Therapeutics, Inc., a Delaware corporation with its principal place of business at 000 Xxxxxxx Xxx, Xxxxx 000, Xxxxxxxxx, XX 00000 (“Acrivon”), and

Akoya Biosciences, Inc., a Delaware corporation with its principal place of business at 000 Xxxxxx Xxxxx, 0xx xxxxx, Xxxxxxxxxxx, XX 00000 (“Akoya”).

Acrivon and Xxxxx are each referred to individually as a “Party” and together as the “Parties.”

Whereas, Acrivon and Xxxxx are parties to that certain Oncosignature Companion Diagnostic Agreement, dated June 17, 2022 (the “Agreement”), under which the Parties are collaborating to develop, validate, obtain regulatory approval for, and commercialize a companion diagnostic test for use with Prexasertib; and

Whereas, the Parties now wish to amend certain terms of the Agreement, as set forth in more detail below.

Now therefore, in consideration of the mutual promises and agreement set forth herein, and for other good and valuable considerations, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

1.Schedule 3.5 of the Agreement is hereby deleted and replaced in its entirety with Schedule 3.5 attached to this First Amendment as Exhibit A.

2.This First Amendment amends the terms of the Agreement as expressly provided above, and the Agreement, as so amended and including all of its other terms and provisions that are not amended, remains in full force and effect. Capitalized terms used but not defined herein shall have the meanings set forth in the Agreement. The validity, performance, construction, and effect of this First Amendment shall be governed by and construed under the substantive laws of the State of Delaware, without regard to conflicts of law rules that would cause the application of the laws of another jurisdiction. This First Amendment may be executed in counterparts, all of which taken together shall be regarded as one and the same instrument.

[Signature Page Follows]

In Witness Whereof, the Parties have executed this First Amendment in duplicate originals by their proper officers as of the First Amendment Effective Date.

Acrivon Therapeutics, Inc. By: /s/ Xxxxx Xxxxx-Xxxxxx Xxxx: Xxxxx Xxxxx-Xxxxxx Xxxxx: Chief Executive Officer Xxxxx Biosciences, Inc. By: /s/ Xxxxx XxXxxxxxxx Xxxx: Xxxxx XxXxxxxxxx Xxxxx: Chief Executive Officer

Exhibit A

Schedule 3.5

Development Milestones; Development Milestone Payments

[***]